Organogenesis Holdings (STU:2PQ) E10: €-0.20 (As of Mar. 2026)


STU:2PQ Organogenesis Holdings Inc STU:2PQ
67 GF Score
Price €2.12
GF Value €2.74
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings E10?

Organogenesis Holdings STU:2PQ 67 E10 is €-0.20 as of Mar. 2026. GuruFocus rates STU:2PQ with a GF Score™ of 67/100 and a GF Value™ of €2.74 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Organogenesis Holdings's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.381. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.20 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-29), Organogenesis Holdings's current stock price is €2.12. Organogenesis Holdings's E10 for the quarter that ended in Mar. 2026 was €-0.20. Organogenesis Holdings's Shiller PE Ratio of today is .


Organogenesis Holdings  (STU:2PQ) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Organogenesis Holdings E10 Related Terms


Organogenesis Holdings E10 Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings E10 Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.16

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.19 -0.16 -0.20

STU:2PQ vs TKNO, AKBA, SIGA: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Shiller PE Ratio falls into.


STU:2PQ
67GF Score
Organogenesis Holdings Inc STU:2PQ
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Organogenesis Holdings's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.381/330.2130*330.2130
=-0.381

Current CPI (Mar. 2026) = 330.2130.

Organogenesis Holdings Quarterly Data

per share eps CPI Adj_EPS
201606 0.000 241.018 0.000
201609 -0.001 241.428 -0.001
201612 -0.415 241.432 -0.568
201703 -0.019 243.801 -0.026
201706 -0.018 244.955 -0.024
201709 -0.252 246.819 -0.337
201712 -0.122 246.524 -0.163
201803 -0.284 249.554 -0.376
201806 -0.257 251.989 -0.337
201809 -0.163 252.439 -0.213
201812 -0.105 251.233 -0.138
201903 -0.150 254.202 -0.195
201906 -0.097 256.143 -0.125
201909 -0.109 256.759 -0.140
201912 -0.036 256.974 -0.046
202003 -0.145 258.115 -0.186
202006 -0.044 257.797 -0.056
202009 0.161 260.280 0.204
202012 0.123 260.474 0.156
202103 0.059 264.877 0.074
202106 0.125 271.696 0.152
202109 0.077 274.310 0.093
202112 0.345 278.802 0.409
202203 -0.009 287.504 -0.010
202206 0.066 296.311 0.074
202209 0.002 296.808 0.002
202212 0.057 296.797 0.063
202303 -0.019 301.836 -0.021
202306 0.037 305.109 0.040
202309 0.019 307.789 0.020
202312 -0.004 306.746 -0.004
202403 -0.018 312.332 -0.019
202406 -0.121 314.175 -0.127
202409 0.081 315.301 0.085
202412 0.038 315.605 0.040
202503 -0.157 319.799 -0.162
202506 -0.087 322.561 -0.089
202509 0.094 324.800 0.096
202512 0.205 324.054 0.209
202603 -0.381 330.213 -0.381

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.20 mean?
Organogenesis Holdings (STU:2PQ) has a E10 of €-0.20 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Organogenesis Holdings and its competitors.
Is Organogenesis Holdings' E10 too high?
Organogenesis Holdings' current E10 is €-0.20. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' E10 compare to TKNO and AKBA?
Organogenesis Holdings' E10 of €-0.20 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Organogenesis Holdings and its competitors. Organogenesis Holdings's current E10 is €-0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (STU:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.74, compared to a current price of €2.12 — trading 22.6% below its estimated fair value. The current E10 is €-0.20. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Organogenesis Holdings (STU:2PQ), the current E10 is €-0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of €2.12 is trading 22.6% below its estimated GF Value™ of €2.74. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for STU:2PQ:

  • E10: €-0.20
  • GF Value™: €2.74 vs. price of €2.12 (22.6% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organogenesis Holdings Business Description

Other Exchanges ORGO:USA2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for STU:2PQ

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.12
Price
€2.74
GF Value